Hospital do Câncer A c. Camargo

A.C. Camargo Cancer Center, formerly known as Hospital do Câncer A.C. Camargo, is Brazil's premier dedicated oncology institution and one of the most prominent cancer centers in Latin America. Founded in 1953 by Dr. Antônio Prudente in the Liberdade district of São Paulo, the center was established with the explicit mission of combating cancer through integrated clinical care, scientific research, and medical education.

The institution is named after Dr. Antônio Camargo Coutinho and operates under the Fundação Antônio Prudente, a non-profit foundation that has guided its development over more than seven decades. Today the center operates approximately 270 beds exclusively dedicated to oncology care, making it one of the largest specialist cancer facilities in Latin America. It handles tens of thousands of new cancer cases annually and provides care across the full spectrum of malignant disease.

The center's affiliation with the Ludwig Institute for Cancer Research (Instituto Ludwig de Pesquisa sobre o Câncer) has established it as one of the most research-intensive cancer hospitals in the southern hemisphere. This partnership drives access to early-phase clinical trials, novel targeted therapies, and genomic medicine platforms that are not available at most institutions in the region.

A.C. Camargo Cancer Center has been consistently recognized as one of Brazil's best hospitals by national and international rankings. Its exclusive oncology focus, research orientation, and multidisciplinary care model position it as the reference destination for patients with complex or rare cancers seeking expert opinion and cutting-edge treatment within Latin America. The center is JCI-accredited, confirming its adherence to international standards for patient safety and clinical quality management.

A.C. Camargo Cancer Center provides comprehensive cancer care through a rigorously multidisciplinary model in which tumor boards of specialist oncologists, surgeons, radiologists, pathologists, and support clinicians jointly plan individualized treatment for every patient. This approach ensures that complex cases receive the benefit of collective expertise rather than single-specialist decision-making.

Medical oncology covers systemic therapies including conventional chemotherapy, targeted molecular therapy, immunotherapy with checkpoint inhibitors, and hormonal therapy for hormone-sensitive cancers. Dedicated disease-site programs address breast cancer, lung cancer, colorectal cancer, genitourinary cancers, gynecological malignancies, head and neck cancers, melanoma, central nervous system tumors, and sarcomas, each with dedicated multidisciplinary teams.

Surgical oncology encompasses complex resections for solid tumors including hepatopancreatobiliary surgery, thoracic oncological surgery, pelvic surgery, head and neck oncological surgery, and soft tissue sarcoma resection. Reconstructive procedures are integrated into surgical planning for aesthetic and functional restoration following tumor removal.

Radiation therapy is delivered using state-of-the-art linear accelerators with IMRT (intensity-modulated radiation therapy), VMAT, stereotactic radiosurgery, and stereotactic body radiation therapy (SBRT) capabilities. Hematology and bone marrow transplantation provide autologous and allogeneic transplant programs for leukemia, lymphoma, multiple myeloma, and aplastic anemia.

Precision oncology and genomic medicine programs use next-generation sequencing to identify targetable mutations and guide treatment selection. Immunotherapy clinical trials offer access to novel agents for patients with refractory or rare malignancies. Palliative care and pain management services provide quality-of-life support alongside active oncological treatment throughout the disease continuum.

A.C. Camargo Cancer Center operates approximately 270 inpatient beds dedicated entirely to oncology care, including a dedicated hematology and bone marrow transplant unit with isolation rooms and positive pressure environments for post-transplant immune recovery. Intensive care capacity supports complex surgical and medically deteriorating oncology patients requiring advanced life support monitoring.

The radiation therapy department is equipped with multiple linear accelerators capable of advanced IMRT, VMAT, SBRT, and stereotactic radiosurgery protocols. Treatment planning is supported by integrated CT simulation and MRI-based contouring for high-precision target delineation. Brachytherapy services are available for gynecological and prostate cancer applications.

The imaging department provides dedicated oncological radiology including multi-slice CT scanning with contrast, 3-Tesla MRI with diffusion and perfusion sequences for tumor characterization, PET/CT for staging and response assessment, and bone scintigraphy. A dedicated nuclear medicine department supports diagnostic and therapeutic nuclear oncology applications.

The molecular diagnostics laboratory is equipped for comprehensive biomarker testing including immunohistochemistry, fluorescence in-situ hybridization (FISH), next-generation sequencing panels, microsatellite instability testing, and liquid biopsy analysis. A biobank supports long-term specimen storage for translational research. Clinical trial infrastructure enables participation in Phase I, II, and III international oncology trials in partnership with the Ludwig Institute and global pharmaceutical sponsors.

A dedicated chemotherapy infusion center provides day-hospital systemic therapy in a comfortable ambulatory setting, with nursing oversight and pharmacist review of all chemotherapy regimens prior to administration. The center is located at Rua Professor Antônio Prudente, 211, Liberdade, São Paulo, and can be contacted at +55 11 2189-5000.

A.C. Camargo Cancer Center is an established destination for international oncology patients seeking expert diagnosis, multidisciplinary tumor board evaluation, second opinions, and specialized cancer treatment in Latin America. English-speaking patient coordinators in the international services team manage the entire process from first contact through treatment and discharge, facilitating specialist appointments, medical record review, treatment plan preparation, and coordination with international health insurers or medical assistance companies.

The center's particular strengths for international patients include expert oncological second opinions from multidisciplinary tumor boards covering all cancer types, access to precision oncology and genomic medicine platforms not widely available outside large research centers, participation in clinical trials for eligible patients with refractory or rare malignancies, and complex surgical oncology capabilities for cases requiring major resective procedures.

São Paulo's status as Latin America's largest city and aviation hub makes international access straightforward. Guarulhos International Airport is approximately 30–40 minutes from the Liberdade campus, with connections to North America, Europe, and all South American capitals. International patients can arrange transportation, hotel accommodation near the campus, and interpreter services through the international patient coordination team.

Treatment costs at A.C. Camargo are significantly lower than equivalent specialized oncology care in North America, Western Europe, or major Asian cancer centers, making it an economically attractive option for uninsured or underinsured patients seeking high-quality cancer treatment without prohibitive expense. The center can be contacted at +55 11 2189-5000, and information is available in English at www.hcanc.org.br/en/.

A.C. Camargo Cancer Center holds Joint Commission International (JCI) accreditation, the global benchmark for hospital quality and patient safety. JCI certification confirms that the center meets international standards across patient identification, medication safety, infection control, surgical safety, clinical governance, and continuous quality improvement, all evaluated through rigorous on-site surveys conducted by international quality assessors.

The center is recognized by Brazil's Ministry of Health as a reference center for oncology and bone marrow transplantation, a designation that requires demonstration of specific clinical volumes, outcomes standards, multidisciplinary team composition, and research productivity. This recognition underpins its role as a national reference for complex cancer care and training.

Affiliation with the Ludwig Institute for Cancer Research connects A.C. Camargo to a global network of cancer research institutions with exacting scientific and ethical standards for human subjects research, biobanking, and clinical trial conduct. The center's research activities are governed by an institutional review board (Comitê de Ética em Pesquisa) ensuring ethical oversight of all clinical research involving patients.

Additional quality frameworks include ANVISA licensing for blood bank, bone marrow transplant, radiation therapy, and laboratory services, compliance with Brazilian Oncology Society (SBOC) clinical practice guidelines, and participation in national cancer registry programs that enable outcome benchmarking against national and international reference standards.